Skip to main content
Clinical Trials/ISRCTN16227145
ISRCTN16227145
Completed
未知

A randomized, controlled, double-blind, double-dummy clinical trial to evaluate the safety and efficacy of Loxoprofen Sodium Cataplasm ointment (Loxonin;PAP100mg) against myalgia

ead Chemical Co. Ltd (Japan)0 sites160 target enrollmentDecember 29, 2014

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
ead Chemical Co. Ltd (Japan)
Enrollment
160
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Registry
who.int
Start Date
December 29, 2014
End Date
August 24, 2011
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ead Chemical Co. Ltd (Japan)

Eligibility Criteria

Inclusion Criteria

  • 1\. Age: \> 18 years, \< 80 years, 18 and 80 years included
  • 2\. Either sex
  • 3\. Any of the following with moderate intensity: resting pain, pressing pain, exercising pain
  • 4\. The patients were not treated by drugs for one week before giving the investigational product, and no change in physiotherapy for 2 weeks during the first treatment.
  • 5\. Patients agree to participate in the trial and sign informed content form after completely understanding the contents of the clinical trial

Exclusion Criteria

  • 1\. Patient's pain caused by external injury and diagnosed as acute
  • 2\. Patient's pain diagnosed as neurosis
  • 3\. Patients with lesions, poor skin conditions on pasting site, or with cutaneous anaphylaxis
  • 4\. Patients who need steroid drugs or other non\-steroid analgesics which may interfere the therapeutic method in this clinical trial.
  • 5\. Patient with peptic ulcer.
  • 6\. Patients with bronchial asthma.
  • 7\. Patients with serious cardiac diseases, hepatic diseases (ALT, AST are equal or bigger than 2\.5 times of upper limit), renal diseases (creatinine is equal or bigger than 1\.5 times of upper limit), hematologic disease, diabetes, mental diseases, and other serious complications.
  • 8\. Pregnant women, lactating mothers or patients who have the possibility of pregnancy, and want to be pregnant during the trial.
  • 9\. Patient allergic to this drug.
  • 10\. Patients participating any clinical trials on investigational drug or marketed drug within 3 months before enrollment or during clinical trial

Outcomes

Primary Outcomes

Not specified

Similar Trials